title: Is the IL-10 -819 polymorphism associated with visceral leishmaniasis?
abstract: Previous investigations demonstrated that immune responses play critical roles in the defense against visceral leishmaniasis (VL). A key regulator of immune responses is the cytokine, IL-10 and polymorphisms within its promoter which could alter its expression. Thus, the aim of this study was to examine the correlation between polymorphism at the -819 position of the IL-10 gene and VL in a selected Iranian population. This cross-sectional study was performed on 100 patients with clinical presentation of VL and seropositive for the leishmania (group 1), 62 patients without clinical presentation but seropositive (group 2), and 128 healthy controls (group 3). The IL-10 -819 polymorphism was evaluated using the PCR-RFLP technique. The anti-leishmania antibody titration was assessed using an immunofluorescence assay. Our results showed that the polymorphism at IL-10 -819 (C/T) position was significantly associated with VL, and C/T genotype was significantly higher in VL patients when compared to groups 2 and 3 (p < 0.001). However, the results demonstrated that the C and T alleles were not associated with VL (p = 0.855). The data presented here confirm the results of previous reports that polymorphisms at the -819 position of the IL-10 gene can influence susceptibility to VL suggesting that the C/T genotype may be considered as a risk factor for the disease.
authors.affiliation: Department of Immunology, Faculty of Medicine, Hamadan University of Medical Sciences, Hamadan, Iran.
authors.forename: Mehrdad
authors.initials: M
authors.lastname: Hajilooi
authors.forename: Kosro
authors.initials: K
authors.lastname: Sardarian
authors.forename: Maryam
authors.initials: M
authors.lastname: Dadmanesh
authors.forename: Mohamad
authors.initials: M
authors.lastname: Matini
authors.forename: Pegah
authors.initials: P
authors.lastname: Lotfi
authors.forename: Ahad
authors.initials: A
authors.lastname: Bazmani
authors.forename: Mohammad Amin
authors.initials: MA
authors.lastname: Tabatabaiefar
authors.forename: Mohammad Kazemi
authors.initials: MK
authors.lastname: Arababadi
authors.forename: Mohammad
authors.initials: M
authors.lastname: Momeni
mesh_terms: D000328:Adult; D000913:Antibodies, Protozoan / Q000097:blood; D003430:Cross-Sectional Studies; D005260:Female; D005787:Gene Frequency; D056726:Genetic Association Studies; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D016753:Interleukin-10 / Q000235:genetics*; D007492:Iran; D007891:Leishmania / Q000276:immunology; D007898:Leishmaniasis, Visceral / Q000235:genetics* / Q000276:immunology; D008297:Male; D020641:Polymorphism, Single Nucleotide; D011401:Promoter Regions, Genetic; D012307:Risk Factors; D055815:Young Adult
chemical_list: D000913:Antibodies, Protozoan; C508609:IL10 protein, human; D016753:Interleukin-10
references.citation: East Mediterr Health J. 2004 Jul-Sep;10(4-5):591-9
references.pmid: 16335651
references.citation: J Biomed Biotechnol. 2010;2010:838390
references.pmid: 20625422
references.citation: J Immunol. 2008 May 1;180(9):6139-48
references.pmid: 18424735
references.citation: Inflammation. 2012 Jun;35(3):797-802
references.pmid: 21909800
references.citation: Hepat Mon. 2010 Winter;10(1):31-5
references.pmid: 22308123
references.citation: J Clin Invest. 1993 Apr;91(4):1644-8
references.pmid: 8097208
references.citation: Trends Immunol. 2007 Sep;28(9):378-84
references.pmid: 17689290
references.citation: Int Immunopharmacol. 2012 Oct;14(2):217-23
references.pmid: 22835429
references.citation: J Infect Dev Ctries. 2011 Jul 04;5(6):473-9
references.pmid: 21727647
references.citation: Exp Parasitol. 2009 Nov;123(3):218-25
references.pmid: 19631209
references.citation: Rev Inst Med Trop Sao Paulo. 1998 Jan-Feb;40(1):31-4
references.pmid: 9713135
references.citation: J Immunol. 2007 Oct 15;179(8):5592-603
references.pmid: 17911647
references.citation: Public Health Genomics. 2010;13(6):362-7
references.pmid: 20051670
references.citation: J Exp Med. 2007 Apr 16;204(4):805-17
references.pmid: 17389235
references.citation: Nephrology (Carlton). 2012 Feb;17(2):167-74
references.pmid: 22070668
references.citation: Microb Pathog. 2005 Apr;38(4):147-60
references.pmid: 15797810
references.citation: Mem Inst Oswaldo Cruz. 2007 Jun;102(4):435-40
references.pmid: 17612762
references.citation: PLoS One. 2011;6(8):e20817
references.pmid: 21857899
references.citation: J Autoimmun. 2003 Jun;20(4):281-5
references.pmid: 12791313
references.citation: J Infect Dis. 2008 Jun 15;197(12):1762-71
references.pmid: 18444882
references.citation: Am J Trop Med Hyg. 2009 Oct;81(4):572-7
references.pmid: 19815868
references.citation: Dermatol Online J. 2012 Dec 15;18(12):32
references.pmid: 23286822
references.citation: Rev Soc Bras Med Trop. 2013 Mar-Apr;46(2):128-34
references.pmid: 23559342
references.citation: J Infect Dis. 2003 Aug 1;188(3):458-64
references.pmid: 12870129
references.citation: Clin Immunol. 2006 Jun;119(3):339-45
references.pmid: 16540374
references.citation: Inflammation. 2013 Feb;36(1):35-41
references.pmid: 22886309
references.citation: Cytokine Growth Factor Rev. 2012 Feb-Apr;23(1-2):47-59
references.pmid: 22390924
references.citation: J Trop Med. 2012;2012:780809
references.pmid: 22253634
references.citation: BMC Infect Dis. 2005 Dec 19;5:113
references.pmid: 16364177
references.citation: J Immunol. 2000 Feb 15;164(4):2001-8
references.pmid: 10657651